MedPath

DANA-FARBER CANCER INSTITUTE

🇺🇸United States
Ownership
-
Established
1947-01-01
Employees
-
Market Cap
-
Website
http://www.dana-farber.org/

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

Completed
Conditions
Childhood Cancer Survivors
Bone Mineral Density
Interventions
Other: Dual energy x-ray absorptiometry (DXA)
Other: Peripheral quantitative computed tomography (pQCT)
First Posted Date
2015-02-04
Last Posted Date
2024-08-06
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
22
Registration Number
NCT02355340
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

Phase 2
Active, not recruiting
Conditions
Chronic Graft-versus-host-disease
Interventions
Procedure: Extracorporeal Photopheresis (ECP)
Drug: Interleukin-2
First Posted Date
2015-01-19
Last Posted Date
2024-01-31
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
25
Registration Number
NCT02340676
Locations
🇺🇸

Dana-Farber Cancer Insitute, Boston, Massachusetts, United States

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Phase 2
Completed
Conditions
Glioblastoma
Interventions
First Posted Date
2015-01-13
Last Posted Date
2020-12-22
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
80
Registration Number
NCT02337491
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy

Not Applicable
Completed
Conditions
Breast Cancer Stage I
Early Stage Breast Cancer
Breast Cancer Stage II
Interventions
Procedure: Intra-operative Magnetic Resonance Imaging (MRI)
Other: Mass Spectrometer Analysis of Tissue Sample
First Posted Date
2015-01-12
Last Posted Date
2023-02-28
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
40
Registration Number
NCT02335671
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase 2
Active, not recruiting
Conditions
HER-2 Positive Breast Cancer
Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Interventions
Drug: T-DM1
Drug: Pertuzumab
Procedure: Excision of tumor/mastectomy
First Posted Date
2014-12-30
Last Posted Date
2024-08-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
164
Registration Number
NCT02326974
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Tennessee Oncology/Sarah Cannon Research Institute, Nashville, Tennessee, United States

🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

Phase 1
Completed
Conditions
Chronic Versus Graft Host Disease
Interventions
First Posted Date
2014-12-17
Last Posted Date
2020-06-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
21
Registration Number
NCT02318082
Locations
🇺🇸

Dana-Farber Cancer Insitute, Boston, Massachusetts, United States

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase 1
Recruiting
Conditions
Glioblastoma
Interventions
Radiation: Radiation Therapy
Biological: Personalized NeoAntigen Peptides
Drug: Pembrolizumab
Biological: Poly-ICLC
Drug: Temozolomide
First Posted Date
2014-11-10
Last Posted Date
2024-12-05
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
56
Registration Number
NCT02287428
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention

Not Applicable
Completed
Conditions
Ovarian Cancer
Interventions
Behavioral: Group Session
Behavioral: Telephone Coaching Session
Behavioral: Webinar
First Posted Date
2014-11-10
Last Posted Date
2020-02-28
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
53
Registration Number
NCT02287519
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Parental Decision-Making for Children With Relapsed Neuroblastoma

Active, not recruiting
Conditions
Relapsed Neuroblastoma
First Posted Date
2014-11-04
Last Posted Date
2024-07-09
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
96
Registration Number
NCT02282735
Locations
🇺🇸

Stanford/Packard's Children's Hospital, Palo Alto, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Columbia University Medical Center, New York, New York, United States

and more 6 locations

Improving Informed Consent for Palliative Chemotherapy

Not Applicable
Completed
Conditions
Metastatic Colorectal Cancer
Unresectable Pancreatic Cancer
Metastatic Pancreatic Cancer
Interventions
Other: Usual, standard-of-care informed consent for chemotherapy
Other: Investigational informed consent for chemotherapy
First Posted Date
2014-11-04
Last Posted Date
2021-10-14
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
216
Registration Number
NCT02282722
Locations
🇺🇸

Dana-Farber at Milford, Milford, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath